MEGA GENOMICS LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.43 HKD | -5.32% |
|
-5.51% | -8.45% |
| Mar. 26 | Mega Genomics Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 12 | Mega Genomics Stockholders to Vote March 1 on Continuing Transactions | MT |
Valuation
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Capitalization 1 | 2,747 | 2,226 |
| Enterprise Value (EV) 1 | 2,349 | 1,748 |
| P/E ratio | -128 x | 66 x |
| Yield | - | - |
| Capitalization / Revenue | 18.8 x | 14.7 x |
| EV / Revenue | 16.1 x | 11.6 x |
| EV / EBITDA | -146 x | 50.6 x |
| EV / FCF | 103,414,764 x | 17,818,205 x |
| FCF Yield | 0% | 0% |
| Price to Book | 4.44 x | 3.45 x |
| Nbr of stocks (in thousands) | 239,234 | 237,769 |
| Reference price 2 | 11.48 | 9.362 |
| Announcement Date | 4/27/23 | 4/26/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net sales 1 | 123.7 | 203.2 | 237.2 | 145.7 | 151.3 |
| EBITDA 1 | 51.93 | 116.3 | 117 | -16.08 | 34.54 |
| EBIT 1 | 43.35 | 107.8 | 108.7 | -24.4 | 26.28 |
| Operating Margin | 35.05% | 53.03% | 45.83% | -16.75% | 17.37% |
| Earnings before Tax (EBT) 1 | 38.29 | 94.9 | 95.88 | -21.42 | 36.18 |
| Net income 1 | 29.69 | 79.1 | 79.02 | -17.62 | 30.04 |
| Net margin | 24% | 38.92% | 33.31% | -12.09% | 19.85% |
| EPS | - | - | 0.6209 | -0.0900 | 0.1418 |
| Free Cash Flow | - | 260 | -193.5 | 22.72 | 98.11 |
| FCF margin | - | 127.94% | -81.58% | 15.59% | 64.85% |
| FCF Conversion (EBITDA) | - | 223.55% | - | - | 284.07% |
| FCF Conversion (Net income) | - | 328.71% | - | - | 326.64% |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 6/9/22 | 6/9/22 | 6/9/22 | 4/27/23 | 4/26/24 |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | 28.5 | 191 | 451 | 398 | 478 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | 260 | -194 | 22.7 | 98.1 |
| ROE (net income / shareholders' equity) | - | 91.1% | 18.1% | -2.68% | 4.76% |
| ROA (Net income/ Total Assets) | - | 18.8% | 11.1% | -2.06% | 2.19% |
| Assets 1 | - | 421.2 | 712.9 | 853.5 | 1,374 |
| Book Value Per Share | - | - | 3.470 | 2.580 | 2.710 |
| Cash Flow per Share | - | - | 1.200 | 1.670 | 2.180 |
| Capex 1 | 0.58 | 1.05 | 4.16 | 5.01 | 35.9 |
| Capex / Sales | 0.47% | 0.51% | 1.75% | 3.44% | 23.7% |
| Announcement Date | 6/9/22 | 6/9/22 | 6/9/22 | 4/27/23 | 4/26/24 |
1CNY in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -8.45% | 302M | |
| -23.00% | 7.93B | |
| +75.81% | 4.54B | |
| +8.70% | 2.77B | |
| -2.80% | 2.62B | |
| -50.25% | 1.99B | |
| -18.67% | 1.7B | |
| -19.73% | 1.47B | |
| +18.95% | 1.23B | |
| -44.86% | 1.1B |
- Stock Market
- Equities
- 6667 Stock
- Financials Mega Genomics Limited
